DeepMed Research

AstraZeneca

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: Public

Employees: 89.9K

Market Cap: $270.3B

Website: http://www.astrazeneca.co.uk

Introduction: AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Clinical Trials

RELEVANCE - RWE Study in Unresectable Non-Small Cell Lung Cancer (Stage III) in Canada

Completed

Conditions: Non-small Cell Lung Cancer

Interventions: Drug: Durvalumab

First Posted Date: 2023-07-06

Last Posted Date: 2023-09-05

Lead Sponsor: AstraZeneca

Target Recruit Count: 662

Registration Number: NCT05933044

Locations: 🇨🇦
Queen Elizabeth (QE) II Health Sciences Centre, Halifax, Nova Scotia, Canada
🇨🇦
The Ottawa Hospital, Ottawa, Ontario, Canada
🇨🇦
University of Calgary, Calgary, Alberta, Canada

and more 2 locations

A Study of Andexanet Alfa in Patients Requiring Urgent Surgery or Procedure

Phase 3

Withdrawn

Conditions: Urgent Surgery

Interventions: Drug: Andexanet alfa
Drug: Usual Care

First Posted Date: 2023-07-03

Last Posted Date: 2024-10-26

Lead Sponsor: AstraZeneca

Target Recruit Count: 800

Registration Number: NCT05926349

Locations: 🇬🇧
Research Site, London, United Kingdom

A Phase 3b, Open-label, Multi-center Study on Durvalumab in Combination With Gemcitabine-based Chemotherapy as 1L Treatment for the Chinese Patients With Unresectable Biliary Tract Cancers (BTC)

Phase 3

Completed

Conditions: Biliary Tract Cancers

Interventions: Drug: durvalumab

First Posted Date: 2023-06-29

Last Posted Date: 2025-04-22

Lead Sponsor: AstraZeneca

Target Recruit Count: 116

Registration Number: NCT05924880

Locations: 🇨🇳
Research Site, Xiamen, China

Determine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY)

Phase 3

Recruiting

Conditions: Systemic Sclerosis
Scleroderma

Interventions: Combination Product: Anifrolumab (blinded)
Drug: Placebo (blinded)
Combination Product: Anifrolumab (unblinded, open label)

First Posted Date: 2023-06-29

Last Posted Date: 2025-04-09

Lead Sponsor: AstraZeneca

Target Recruit Count: 306

Registration Number: NCT05925803

Locations: 🇻🇳
Research Site, Hochiminh, Vietnam

Study to Assess Neoadjuvant Durvalumab (D) and Platinum-Based Chemotherapy (CT), Followed by Either Surgery and Adjuvant D or CRT and Consolidation D, in Resectable or Borderline Resectable Stage IIB-IIIB NSCLC (MDT-BRIDGE)

Phase 2

Recruiting

Conditions: Non-small Cell Lung Cancer

Interventions: Drug: Durvalumab

First Posted Date: 2023-06-29

Last Posted Date: 2025-05-15

Lead Sponsor: AstraZeneca

Target Recruit Count: 140

Registration Number: NCT05925530

Locations: 🇸🇪
Research Site, Uppsala, Sweden

Tezepelumab PRO Study

Active, not recruiting

Conditions: Asthma

First Posted Date: 2023-06-28

Last Posted Date: 2025-04-27

Lead Sponsor: AstraZeneca

Target Recruit Count: 92

Registration Number: NCT05922891

Locations: 🇯🇵
Research Site, Yonago, Japan

A Non-interventional Prospective Study of 1-st Line Treatment Approaches in OVArian Cancer Patients With HRD+ Status in Russian Federation

Active, not recruiting

Conditions: Ovarian Cancer

First Posted Date: 2023-06-26

Last Posted Date: 2025-04-06

Lead Sponsor: AstraZeneca

Target Recruit Count: 400

Registration Number: NCT05918042

Locations: 🇷🇺
Research Site, Yaroslavl, Russian Federation

Study on Determine the Utilisation and Clinical Outcomes of Evusheld in COVID-19 PrEP in China

Completed

Conditions: COVID-19

First Posted Date: 2023-06-26

Last Posted Date: 2024-05-29

Lead Sponsor: AstraZeneca

Target Recruit Count: 248

Registration Number: NCT05917951

Locations: 🇨🇳
(2) Ruijin-Hainan Hospital Shanghai Jiaotong University School of Medicine (Hainan Boao Research Hospital), Qionghai, Hainan, China

A Phase I Study to Investigate the Effect of Hepatic Impairment on the PK, Safety, and Tolerability of AZD2693

Phase 1

Completed

Conditions: Hepatic Impairment

Interventions: Drug: AZD2693

First Posted Date: 2023-06-26

Last Posted Date: 2024-11-25

Lead Sponsor: AstraZeneca

Target Recruit Count: 36

Registration Number: NCT05919069

Locations: 🇺🇸
Research Site, Orlando, Florida, United States

HER2-low Unresectable and/or Metastatic Breast Cancer in Russia

Recruiting

Conditions: Breast Cancer

First Posted Date: 2023-06-22

Last Posted Date: 2025-03-18

Lead Sponsor: AstraZeneca

Target Recruit Count: 1500

Registration Number: NCT05913440

Locations: 🇷🇺
Research Site, Yuzhno-Sakhalinsk, Russian Federation

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy